CD95 Polypeptides

JP2024541501APending Publication Date: 2024-11-08DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024531209
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-25
Filing Date
2022-11-24
Publication Date
2024-11-08

Smart Images

  • Figure 2024541501000001
    Figure 2024541501000001
  • Figure 2024541501000002
    Figure 2024541501000002
  • Figure 2024541501000003
    Figure 2024541501000003
Patent Text Reader

Abstract

The present invention relates to an effector polypeptide comprising: (i) an amino acid sequence that is at least 70% identical to the amino acid sequence RSNLGWLCLLLLPIPLIVWVKRK (SEQ ID NO:1); and (ii) an amino acid substitution with a non-identical amino acid at at least one position selected from the group consisting of positions 1, 2, 3, 19, 22, and 23 of the amino acid sequence of (i). The present invention also relates to polynucleotides comprising nucleic acid sequences encoding said effector polypeptide, as well as related host cells, pharmaceutical compositions and uses, further related uses in the field of medicine, in particular in the treatment and / or prevention of cancer, inflammatory diseases, or acute or chronic neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Chimeric protein

    JP2018512154A

  • Immunomodulatory fusion proteins and uses thereof

    JP2020511136A

  • Immunomodulatory fusion proteins and uses thereof

    WO2018170475A1

  • cell

    WO2021205176A2

  • Compositions and methods for cellular immunotherapy

    WO2022132836A2